SCHEMBL3328331

SCHEMBL3328331

NNC(=O)CCCS

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12641478 0.92
SCHEMBL29240120 0.90 ALDH1A1 (0.55)
SCHEMBL1962359 0.83
SCHEMBL28219205 0.83 ALDH1A1 (0.62)
SCHEMBL218953 0.83 KDM4E (0.60)
SCHEMBL49856 0.83 ALDH1A1 (0.62)
Methane SCHEMBL9381644 0.81
SCHEMBL4187314 0.80 KDM4E (0.65)
SCHEMBL4186692 0.80 ALDH1A1 (0.67)
Ammonia Solution, Strong SCHEMBL15129241 0.80 ALDH1A1 (0.60)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3095467-B1 ANTIBODY-ENZYME CONJUGATE VENTANA MED SYST INC (US) 2020-05-06 EP claimed
EP-2963011-B1 MOLECULAR CONJUGATE VENTANA MED SYST INC (US) 2018-05-09 EP claimed
EP-3095467-A1 MOLECULAR CONJUGATE Ventana Medical Systems, Inc. (US) 2016-11-23 EP claimed
US-20160195540-A1 Molecular Conjugate VENTANA MED SYST INC (US) 2016-07-07 US claimed
US-9310373-B2 Molecular conjugate VENTANA MEDICAL SYSTEMS, INC. (US) 2016-04-12 US claimed
EP-2963011-A1 MOLECULAR CONJUGATE Ventana Medical Systems, Inc. (US) 2016-01-06 EP claimed
US-20140205995-A1 MOLECULAR CONJUGATE VENTANA MEDICAL SYSTEMS, INC. (US) 2014-07-24 US claimed
US-20260109728-A1 IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE TALLAC THERAPEUTICS INC (US) 2026-04-23 US disclosed
US-12351598-B2 Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use Tallac Therapeutics, Inc. (US) 2025-07-08 US disclosed
US-12280021-B2 Affinity medicant conjugate AF CHEMICALS, LLC (US) 2025-04-22 US disclosed
US-20230372267-A1 AFFINITY MEDICANT CONJUGATE Califia Pharma Inc. (US) 2023-11-23 US disclosed
US-20220056069-A1 IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE HORIZON TECHNOLOGY FINANCE CORPORATION 2022-02-24 US disclosed
US-11241398-B2 Affinity medicant conjugate AF CHEMICALS, LLC (US) 2022-02-08 US disclosed
WO-2008153744-A2 POLYMERIC CARRIERS FOR IMMUNOHISTOCHEMISTRY AND IN SITU HYBRIDIZATION VENTANA MEDICAL SYSTEMS, INC. (US) 2008-12-18 WO disclosed
EP-1951316-A2 MOLECULAR CONJUGATE Ventana Medical Systems, Inc. (US) 2008-08-06 EP disclosed
WO-2007062177-A2 MOLECULAR CONJUGATE VENTANA MEDICAL SYSTEMS, INC. (US) 2007-05-31 WO disclosed
WO-2007062177-A2 MOLECULAR CONJUGATE VENTANA MEDICAL SYSTEMS, INC. (US) 2007-05-31 WO disclosed
US-20070117153-A1 Molecular conjugate VENTANA MEDICAL SYSTEMS, INC. 2007-05-24 US disclosed
US-20070117153-A1 Molecular conjugate VENTANA MEDICAL SYSTEMS, INC. 2007-05-24 US disclosed
US-20070117153-A1 Molecular conjugate VENTANA MEDICAL SYSTEMS, INC. 2007-05-24 US disclosed